Anti-interleukin 5 therapy for chronic rhinosinusitis with polyps.

Area of Science:

• Otolaryngology
• Immunology
• Pharmacology

Background:

• Chronic rhinosinusitis (CRS) is sinonasal mucosa inflammation exceeding 12 weeks.
• Two forms exist: CRS with polyps (CRSwNP) and without polyps.
• CRSwNP involves elevated interleukin 5 (IL-5), crucial for eosinophil development and survival.

Purpose of the Study:

• To evaluate the effectiveness of interleukin 5 inhibition as a treatment for chronic rhinosinusitis with polyps.
• To assess the safety profile of IL-5 inhibitors in this patient population.

Main Methods:

• A comprehensive search of systematic reviews was conducted using Epistemonikos, a large health database.
• Data from systematic reviews were extracted, primary study data reanalyzed, and a meta-analysis performed.
• The GRADE approach was utilized to generate a summary of findings table.

Main Results:

• Three systematic reviews, encompassing three randomized trials, were identified.
• Interleukin 5 inhibitors demonstrated a potential to decrease nasal polyp scores.
• Adverse effects were reported as infrequent and of low severity.

Conclusions:

• Interleukin 5 inhibition shows promise in reducing nasal polyps in CRSwNP.
• The observed adverse effects associated with IL-5 inhibitors are generally mild and uncommon.
• The overall certainty of the evidence supporting this therapeutic approach is currently low.